Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.9M | $177M | $248M | $351M | $494M | $535M | $538M | $509M | $605M | $655M |
| Revenue growth | — | 113.6% | 40.1% | 41.6% | 40.7% | 8.2% | 0.5% | -5.3% | 18.8% | 8.3% |
| Gross profit | $36.6M | $121M | $168M | $263M | $388M | $420M | $423M | $381M | $468M | $488M |
| Gross margin | 44.2% | 68.6% | 67.7% | 74.8% | 78.5% | 78.5% | 78.6% | 74.8% | 77.3% | 74.5% |
| Operating income | -$115M | -$39.3M | -$33.7M | -$914K | $30.4M | -$44.3M | -$89.5M | -$233M | -$170M | -$154M |
| Operating margin | -139.1% | -22.2% | -13.6% | -0.3% | 6.1% | -8.3% | -16.6% | -45.7% | -28.2% | -23.5% |
| Net income | -$132M | -$61.7M | -$63.6M | -$7.23M | $19.8M | -$58.4M | -$92.5M | -$207M | -$169M | -$136M |
| Net margin | -159.1% | -34.8% | -25.6% | -2.1% | 4.0% | -10.9% | -17.2% | -40.6% | -27.9% | -20.8% |
| EPS (diluted) | -$1.54 | -$0.70 | -$0.69 | -$0.07 | $0.18 | -$0.56 | -$0.88 | -$1.95 | -$1.56 | -$1.22 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$108M | -$33.1M | -$1.86M | $26.6M | $99.1M | $82.8M | $30.8M | -$73.3M | -$26.4M | -$49.0M |
| Capital expenditures | $5.67M | $7.37M | $6.71M | $10.5M | $15.0M | $24.2M | $21.4M | $27.1M | $42.9M | $26.6M |
| Free cash flow | -$113M | -$40.5M | -$8.58M | $16.1M | $84.2M | $58.6M | $9.43M | -$100M | -$69.2M | -$75.7M |
| Dividends paid | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $99.8M | $78.6M | $141M | $177M | $235M | $209M | $115M | $241M | $164M | $93.5M |
| Total assets | $282M | $265M | $340M | $479M | $1.05B | $1.14B | $1.19B | $1.15B | $1.24B | $804M |
| Total liabilities | $140M | $152M | $228M | $262M | $575M | $729M | $750M | $784M | $881M | $464M |
| Long-term debt | $96.2M | $97.3M | $149M | $149M | $430M | $562M | $566M | $569M | $97.3M | $195M |
| Shareholders' equity | $142M | $114M | $112M | $218M | $477M | $410M | $441M | $362M | $360M | $340M |
| Retained earnings | -$520M | -$582M | -$644M | -$651M | -$631M | -$686M | -$778M | -$986M | -$1.15B | -$1.29B |
| Shares (wtd avg diluted) | 87.1M | 89.5M | 91.8M | 97.2M | 109M | 103M | 105M | 106M | 108M | 111M |
Every figure is extracted from NovoCure Ltd’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.